Pluri
Messaging for a Publicly Traded Biotech Innovator
From brand development to ringing the closing bell at NASDAQ
Situation
Pluri is a biotech company pushing the boundaries of science and engineering through innovative cell therapies and next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity’s greatest challenges.
Pluri has an unmatched capability to design and manufacture cell-based products at industrial scale, and recently launched a new venture to create high-quality and sustainable cultured meat with Tnuva, Israel’s largest food company.
Approach
Miller Ink developed a comprehensive set of messages tailored to each of Pluri’s focuses and created an in-depth press plan to secure media coverage of its events.
As Pluri’s work spans the medical and tech fields, the company partners with a wide range of government and industry organizations—from the Department of Defense and the FDA to Nasdaq and TASE (Tel-Aviv Stock Exchange). Miller Ink provides ongoing communications support and media strategy for these partnerships, including writing content for new ventures, pitching journalists to cover news updates, and securing interviews and participation in industry events.
Impact
Miller Ink brought together community leaders and top media to cover Pluri’s ringing the closing bell at Nasdaq in March 2022 and secured articles from FOX Business and Jewish Telegraphic Agency.
Our team also organized and prepared the Pluri team for an online webinar with American Jewish University and an exclusive conversation with Jewish National Fund USA.
After Pluri launched their joint venture with Israeli food giant Tnuva, our team secured placement of nearly 100 unique stories including market press (Yahoo! Finance), food press (Food Navigator), and Jewish media (Jerusalem Post). These articles led to interest from investors as well as invitations for Pluri to participate in trade conferences.
